TP53 and glioblastoma: Furthermore, while extended TMZ treatment did not significantly prolong PFS in p53 wild-type GBM patients (mPFS: 15.50 months vs. 11.50 months, HR = 2.26, 95% CI: 0.74 ~ 6.90, P = 0.068), this treatment regimen did dramatically improve PFS in GBM patients with mutant p53 (mPFS: 13.15 months vs. 9.30 months, HR = 1.57, 95% CI: 0.96 ~ 2.56, P = 0.046) (Figure 5B).